Amplification of fibroblast growth factor receptor 1 ( FGFR1 ) has been reported in many squamous cell carcinomas, and human papillomavirus (HPV) -related oropharyngeal squamous cell carcinoma has been characterized as a distinct subset with favorable prognosis. Here, we investigated the FGFR1 amplification and HPV status in tonsillar squamous cell carcinoma (TSCC) and analyzed the clinical characteristics. HPV in situ hybridization (HPV ISH) and FGFR1 fluorescence in situ hybridization (FISH) were performed using tissue microarray from 89 cases of TSCC. Fourteen of 89 (15.7%) TSCC cases had FGFR1 amplification, and HPV was detected in 59 of 89 (66.3%) cases. FGFR1 amplification status was not associated with HPV positivity ( p =0.765). Outcomes were not significantly different between FGFR1 amplified and non-amplified patients. Although FGFR1 amplified patients ( n =4) in the HPV ISH -negative group ( n =30) had a tendency for poorer overall survival, no statistical significance was identified ( p =0.150, log-rank). FGFR1 protein overexpression showed better disease-free survival ( p =0.031, log-rank) in HPV-negative TSCC. This study suggests FGFR1 amplification may be important in the pathogenesis of TSCC regardless of HPV status. (J Histochem Cytochem 66:511 -522, 2018) Keywords fibroblast growth factor receptor 1 , fluorescence in situ hybridization , human papillomavirus , squamous cell carcinoma , tonsil
Introduction
Approximately 50,000 new cases of oral cavity and pharyngeal cancer are expected to be diagnosed, and 10,000 related deaths are estimated to occur in the United States. 1 Despite enormous cancer treatment efforts, the 5-year survival rate is about 50%. 2 The most important risk factors for oral cavity and pharyngeal cancer are tobacco use and alcohol consumption. Human papillomavirus (HPV) infection is an additional independent risk factor in oropharyngeal carcinoma. 3 It is well known that HPV-associated head and neck 761652 JHC XX X 10.1369/0022155418761652 FGFR1 Amplifi cation in Tonsillar Squamous Cell Carcinoma Park et al.
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squamous cell carcinoma (HNSCC) shows a good prognosis compared with non-HPV-infected patients. 4 Comprehensive molecular profiling for human cancer is a major trend in the area of cancer research, and the identification of genomic alterations for specific malignancies leads to a better understanding of tumor biology and the development of target therapies. 5, 6 Fibroblast growth factor receptor 1 (FGFR1) is a member of four tyrosine kinase receptor family, encoded by a gene located on chromosome 8p12.1. 7 Amplification of FGFR1 has been recently reported in lung, 8 breast, 9 and head and neck squamous cell carcinomas, 10 and sensitivity to FGFR1 tyrosine kinase inhibitors in preclinical models and developed candidates of FGFR tyrosine kinase inhibitors have been reported, leading to clinical trials of these agents in FGFR1 amplified tumors. 11, 12 However, knowledge of the clinical and prognostic significance of FGFR1 amplification in patients with tonsillar squamous cell carcinoma (TSCC) and the relationship between HPV status and FGFR1 amplified TSCC is limited. Thus, in the present study, we investigated the prognostic significance of FGFR1 amplified TSCC and analyzed the association between HPV status and FGFR1 amplification.
Patients and Methods

Patients
This study was conducted in a cohort of patients with TSCC who underwent surgery and neoadjuvant and/ or postoperative adjuvant chemoradiotherapy between January 2000 and December 2010 at Asan Medical Center, Seoul, Korea. There were 280 patients with squamous cell carcinoma diagnosed in tonsil. The exclusion criteria were patients without tissue block (n=61), patients performed only punch or needle biopsy (n=120), and patients having history of squamous cell carcinoma from larynx, tongue, esophagus, lung, and so on, previously or synchronously (n=10). The criteria used for patient selection included the availability of tumor tissue from primary TSCCs as well as data on smoking status and survival. These were summarized in Fig. 1 . This study cohort was previously published by Lee et al. 13 The study was approved by the Institutional Review Board of Asan Medical Center. Smoking history was measured in pack-years and classified into three categories: nonsmoker, former smoker who quit smoking more than 10 years ago, or current smoker. Alcohol consumption was defined as having no history of alcohol use, having three or less drinks per day, or having more than three drinks per day. Tumor samples were available for 89 patients. The patient population included 81 (91.0%) males and 8 (9.0%) females with a median age of 55 years. Twentyeight patients (31.5%) were never smokers, and 53 (59.6%) were current smokers. Follow-up periods ranged from 7 to 135 months with a median follow-up of 55 months. The recurrence rate was 15.7% (14/89).
Tissue Microarray Construction and Immunohistochemistry
We used the previously published tissue microarray (TMA). 13 Briefly, TMAs were constructed from 2-mm cores of representative tumor areas from paraffinembedded blocks, in duplicate. TMAs were used in immunohistochemical staining of p16 and FGFR1, fluorescence in situ hybridization (FISH) for FGFR1 gene amplification, and HPV in situ hybridization (HPV ISH).
Immunohistochemistry (IHC) was done with antibodies for p16 (1:10, monoclonal p16
INK4
; Pharmingen, San Diego, California) and FGFR1 (cat. no. BS5569; 1:500, polyclonal rabbit anti-FGFR1; Bioworld, St Louis Park, Minnesota) using the Ventana NX automated IHC system (Ventana Medical Systems, Tucson, Arizona) with OptiView DAB Detection Kit (Ventana Medical Systems) according to the manufacturer's instructions and using the reagents supplied with the kit. In brief, sections of 4 μm were mounted on silanized charged slides and allowed to dry for 10 minutes at room temperature, followed by 20 min in an incubator at 65C. After deparaffinization, heat-induced antigen retrieval was performed using pH 6.0 citrate buffer (CC1 Protocol; Ventana Medical Systems), and incubated for 32 min with primary antibodies at room temperature. The slides were counterstained with hematoxylin. As positive control, we used squamous cell carcinoma of the lung for FGFR1 and uterine cervical squamous cell carcinoma for p16. As negative control, we used adenocarcinoma of the lung for FGFR1 and normal lung tissue. p16 INK4 expression was regarded as positive if the nuclei and/or cytoplasm were strongly and diffusely stained in ≥70% of the tumor cells.
14 FGFR1 expression was semiquantitatively scored according to cytoplasmic and membranous stain, as described previously 15 : 0, no expression; 1, ≤10% positive; 2, 10-50% positive; and 3, ≥50% positive. Representative IHC images were shown in Fig. 2 . For statistical analysis, the FGFR1 scores were divided into two groups: positive (2 and 3) versus negative (0 and 1).
FGFR1 Fluorescence In Situ Hybridization
We performed the FISH assay using a commercially available FGFR1 probe (cat. no. LPS018, Aquarius, FGFR1 Breakapart/Amplification probe; Cytocell, Cambridge, United Kingdom). The FGFR1 probe mix consists of a green 267-kb probe telomeric to the FGFR1 gene (8p12) spanning the LETM2 gene and D8S135 marker, and a red probe that is 272 kb centromeric to the FGFR1 gene (8p12) spanning a 108-kb region, including the D8S389 and D8S2317 markers. An accompanying 8-centromere probe (D8Z2, 8p11.1-q11.1) in blue acted as a control for chromosome 8. FISH analyses were interpreted by two experienced evaluators (J.S.S. and M.L.) who were blinded to the clinical data. At least 40 nuclei per patient were evaluated. As there are currently no standard criteria for the definition of FGFR1 FISH positivity, we defined it as follows: For the FGFR1 gene amplified group, more than 2.2 copies of the gene was considered to be positive. The copy number control ratio and FGFR1 nonamplified group had fewer than 2.2 copies. 16 
HPV In Situ Hybridization
The 
DNA Extraction
HPV ISH-negative, p16-positive cases were retested by HPV DNA chip. We obtained the blocks for HPV genotyping with the same samples previously used for TMA. DNA was extracted from formalin-fixed paraffinembedded tissue using a LaboPass Tissue Mini DNA Purification Kit (Cosmo Genetech, Seoul, Korea). Paraffin-embedded tumor tissues were cut into 20-µm-thick sections, using disposable microtome blades, and three consequent sections were collected using microcentrifuge tubes. Then, two extractions were mixed with 1.2 mL of xylene, and excess xylene was removed by two 1.2-mL 100% ethanol washes. Dried tissue samples were incubated with lysis buffer and proteinase K at 56C for 30 min. Subsequently, the mixture was applied to the spin column and centrifuged into a collection tube according to the manufacturer's protocol. The purified DNA was used directly for polymerase chain reaction (PCR).
HPV Genotyping
A commercially available HPV DNA chip (Goodgene, Seoul, Korea) was used for HPV genotyping. The HPV DNA chip contained 40 type-specific probes, including 21 types of high-risk HPV (16, 18, 26, 31, 33, 35, by PCR with primer sets, which target L1 and L2 regions of HPV DNA. The amount of DNA was 10 µl. As a control gene, the human β-globin gene was also amplified. The PCR products from all samples were detected by electrophoresis using 2% agarose gels, and the HPV DNA product size was 185 bp. Hybridized HPV DNA was visualized using a DNA chip scanner (GeneScan; Goodgene). To avoid contamination that may yield a false-positive result, all PCR-related work was performed in specialized zones within a PCR laboratory. 13 
Statistical Analysis
Statistical analyses were performed using SPSS version 18.0 (Statistical Package for Social Science, SPSS Inc., Chicago, IL). Comparisons of clinicopathologic variables between the FGFR1 amplified and non-amplified groups were made, using chi-square or Fisher's exact test for nominal variables. The overall survival (OS) and disease-free survival (DFS) were compared using the Kaplan-Meier method, and the survival differences were calculated by the log-rank test. All p values less than .05 were considered to be statistically significant.
Results
Frequency of FGFR1 Gene Amplification and Association With Clinical Characteristics
Fourteen of 89 (15.7%) TSCC cases showed FGFR1 gene amplification by FISH, and the average amplification ratio was 4.78 (Fig. 3) . The clinicopathologic characteristics were compared between the 14 FGFR1 gene amplified cases and the 75 non-amplified FGFR1 gene cases, summarized in Table 1 . The mean age of the FGFR1 gene amplified and non-amplified patients was 52.8 and 55.6 years old, respectively. However, these ages were not significantly different (p=0.489). The FGFR1 gene amplified group was not associated with any clinicopathologic variables, including pT stage (p=0.609), pN stage (p=0.790), pTNM stage (p=0.795), and alcohol history (p=0.297). With respect to smoking habits, five of 14 (17.9%) FGFR1 gene amplified cases were never smokers, and 9 of 14 (48.8%) FGFR1 gene amplified cases were smokers, but no statistical significance was observed between the two groups (p=0.155).
FGFR1 Protein Expression and Association With Clinicopathologic Variables
The results are summarized in Table 1 
Association of FGFR1 Gene Amplification With HPV Status and p16
We used partly previously published data 13 of HPV ISH, p16, and HPV genotyping. Fifty-nine of 89 (66.3%) TSCC patients showed HPV ISH positivity, and 74 of 89 (83.1%) TSCCs showed p16 immunopositivity (Supplementary Figure 1) . A strong positive correlation between p16 expression and HPV status (p<0.001) was identified (Supplementary Table 1 ). However, no survival benefit according to HPV and p16 status was observed (Supplementary Figure 3. ).
Thirty-six of 89 (40.4%) TSCC patients showed immunopositivity for FGFR1 protein, but no correlation was found between FGFR1 gene amplification and FGFR1 protein expression (p=0.115).
HPV genotyping using a DNA chip was performed. No HPV DNA was detected by genotyping in all 17 cases. To overcome the restricted HPV genotyping (p16 + /HPV ISH -, n=17), we analyzed HPV genotyping with validation set (n=83) and the results described in Supplementary Material 2, Supplementary Figure 2 , and Supplementary Tables 1 and 2 .
Ten of 14 (71.4%) patients of the FGFR1 gene amplified group showed HPV ISH positivity, and 9 (64.3%) of the FGFR1 gene amplified patients showed immunopositivity for p16. However, no correlations were observed between HPV ISH and FGFR1 gene amplification (p=0.765) or p16 expression and FGFR1 gene amplification (p=0.055).
Survival Outcomes According to FGFR1 Amplification and FGFR1 Protein Expression
The OS and DFS rates (DFS) between the amplified FGFR1 group and non-amplified group did not show statistical significance (p=0.865, log-rank, and p=0.637, log-rank, respectively, Fig. 4 ). When restricting the analysis to the HPV-negative group only (n=30), a survival benefit of the amplified versus the nonamplified FGFR1 group was not observed (p=0.150, log-rank, and p=0.586, log-rank, respectively). In addition, no significant survival benefit was observed among smokers (n=53), whether the patients had the amplified FGFR1 gene or not. For FGFR1 protein expression, the OS (p=0.082, log-rank) and DFS (p=0.458, log-rank) were not statistically different whether FGFR1 was expressed or not. However, when restricting the analysis to the HPVnegative group only (n=30, Fig. 5 ), the FGFR1 protein positive expression group (n=11) had better DFS (p=0.031, log-rank), while OS was not different from the FGFR1 protein expression negative group (p=0.076, log-rank).
Discussion
We reported FGFR1 amplification and protein expression in patients with TSCC and analyzed the association between FGFR1 amplification or protein expression and HPV status. We reviewed the published studies on PubMed for FGFR1 amplification and FGFR1 protein expression in HNSCC and summarized in Table 2 . In brief, the frequency of FGFR1 amplification ranged from 0.8% to 20%, and FGFR1 amplified patients were free of HPV infection. Association with smoking in amplified patients was controversial. No OS differences between the FGFR1 amplified and non-amplified groups were noted, although previous studies revealed that high protein expression was a poor prognostic factor.
We performed in silico analysis for TCGA Head and Neck Squamous Cell Carcinoma (TCGA-HNSCC) and compared TCGA data with our data (Supplementary Material 1). Our study revealed a relatively high frequency of FGFR1 amplification (15.7%) compared with TCGA data, which showed FGFR1 amplification in 10.0% of HNSCCs. Freier et al reported the FGFR1 amplification frequency to be 17.4% in oral squamous cell carcinoma, 15 but Ozretic et al reported 5.6% in oropharyngeal squamous cell carcinoma. 17 These differences could be explained by the following factors. First, the definition of amplified FGFR1 was not fully standardized. The cutoff values ranged from 2.0 to 9.0 in the published English literature. 16, 26, 27 Second, the specimen populations of the previous studies were heterogeneous in that they reported on various squamous cell carcinomas of the head and neck, including the oral cavity, larynx, salivary gland, oropharynx, and even sinonasal cavity. However, our study was the most homogeneous given that we focused only on TSCC. Third, different detection methods were used among the studies; the applied methods included FISH/silver in situ hybridization (SISH), next-generation sequencing, mRNA expression, and so on.
For the relationship between FGFR1 amplification and HPV status, published TCGA data 22 revealed that there were no HPV-positive patients among those with FGFR1 amplification, but our data showed that 10 (71.4%) patients with FGFR1 amplification had positive HPV ISH results. As shown in Table 2 , FGFR1 amplified patients had a tendency to lack HPV infection; however, not all FGFR1 amplified patients showed HPV negativity. Ozretic et al. 17 reported that 8% (1/13) of FGFR1 amplified patients had HPV-16 Figure 5 . Survival analysis for FGFR1 protein expression in patients with HPV in situ hybridization negativity. FGFR1 is a poor prognostic factor for recurrence (p=0.031, log-rank, B), while no prognostic significance is observed in overall survival (p=0.076, log-rank, A). Abbreviations: FGFR1, fibroblast growth factor receptor 1; HPV, human papillomavirus. DNA positivity. A reason for these results may be racial differences and varying specimen purity. The incidence of HPV in the Korean population ranges from 37% to 67%, 4, 13 whereas Western data have shown a range of 37-80%. 28, 29 In general, oropharyngeal squamous cell carcinoma showed a higher frequency of HPV than other HNSCCs (79% vs. 21%, respectively). 21 The detection method used cannot explain the differences in HPV status among the FGFR1 amplified patients. The sensitivity of HPV ISH was known to be 88%, whereas that of DNA quantitative PCR was 97%. 30 In other words, HPV ISH had higher false negativity. Therefore, our results support the notions that FGFR1 amplification was not associated with HPV status, and that FGFR1 amplification occurred regardless of HPV status.
Kim et al. 26 and Seo et al. 31 et al revealed that high copy FGFR1 amplification was associated with heavy smoking in squamous cell carcinoma of the lung. In contrast, Heist et al. 16 suggested that FGFR1 amplification was not associated with smoking. To this end, the association of smoking with FGFR1 amplification in HNSCC is still controversial. Ozretic et al., 17 Göke et al., 10 and Young et al. 24 reported that high FGFR1 amplification was associated with smoking in HNSCC, but Schröck et al. 23 reported that there was no such association. Our study showed that there was no association between FGFR1 amplification and smoking.
Gene amplification and protein expression show different correlations according to the target. Amplification of Her2/neu (human epidermal growth factor receptor 2) gene amplification in breast cancer and its protein c-erb2 expression are well correlated; thus, IHC for c-erb2 is used as a screening method for the selection of patients who have to be treated with trastuzumab, which is only used on patients with Her2/neu gene amplification by FISH. However, as seen in our report and others, FGFR1 amplification and FGFR1 protein expression in HNSCC are not correlated with each other.
15 FGFR1 protein expression was more frequent (12-75%) than gene amplification. 15, 18 Our study revealed FGFR1 protein in 39.3% and FGFR1 gene amplification in 15.7% of cases and there was no correlation between protein expression and gene amplification (p=0.797).
The prognosis of FGFR1 amplification is controversial not only in HNSCC but also in squamous cell carcinoma of the lung. Three previous studies 26, 31, 32 reported that amplified FGFR1 was a poor prognostic factor in non-small cell carcinoma, but Jiang et al reported by meta-analysis of four studies 33 that FGFR1 amplification had no influence on OS. In addition, all published studies of FGFR1 amplification in HNSCC showed no prognostic significance for OS (Table 2) . However, Koole et al. 18, 19 reported that high expression of FGFR1 protein was related with poor prognosis.
Our study had several limitations: First, the numbers of the cases were relatively small; second, selection bias was present. The submitted cohort contained patients only with an adequate amount of specimen from tonsillectomy for TMA excluding inoperable cases with higher stage, which may affect the analysis of relationship between FGFR1 amplified squamous cell carcinoma and survival rate. Third, incomplete test for HPV genotyping was performed. Although we tried to additionally test for the other samples except HPV ISH -/p16 + cases at the time of writing, we could not buy the same genotyping chip kit that we previously tested due to the company failure. Moreover, half of the samples were too old to extract DNA and the quality of the DNA was very poor. To overcome this issue, we tried to validate the results of HPV genotyping based on the medical record. These were described in Supplementary Material 2 and Supplementary Tables 1 and 2 . Last, we could not determine the sensitivity and specificity of anti-FGFR1 antibody because of discordance between FGFR1 amplification and FGFR1 protein expression (p=0.797) and just fully relied on the manufacturer's instruction.
The identification of genetic alterations in multiple FGFR family members in human cancers highlights pan-FGFR inhibition as a promising therapeutic approach in a variety of malignancies. Several smallmolecule FGFR inhibitors with differing selectivity and potency profiles, such as brivanib, dovitinib, AZD4547, BGJ398, and erdafitinib, are in various stages of clinical development. Dovitinib, 34 AZD4547, 18 and BJG398 35, 36 showed good responses in HNSCC at the preclinical level.
In conclusion, our study showed that FGFR1 amplification was frequently observed in patients with TSCC, not associated with HPV status and not associated with prognosis. Our study suggests that FGFR1 amplification may be important in pathogenesis regardless of HPV status. Further study is required that FGFR1 amplification in TSCC correlates with response to targeted anti-FGFRs drugs.
